Skip to Main Content

Zogenix (ZGNX) closed out September’s crammed clinical trial calendar with an impressive win.

The small biotech company, based in Emeryville, Calif., said its lead drug, ZX008, significantly reduced seizure activity compared to a placebo in children with Dravet syndrome, a rare and severe type of epilepsy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!